Welcome Snackers, today’s snack will cover the market developments of DFDS and Elicera Therapeutics AB .
Today’s Market Movements
Denmark:
OMX:C25 (0.4%)
Sweden:
OMX:S30 (-0.61%)
Norway:
OBX:OSL (-0.05%)
S&P 500 (0.18%)
Nasdaq (-0.2%)
Today’s European markets put an end to last weeks downtrend, with the C25 rising 0.4% after four successive days of losses at the end of last week. Market sentiment in the US is also positive as markets have seemingly come to terms with a dialling down of Federal Reserve stimulus. In Denmark, the green energy sector was a significant driver of the upwards movements as Vestas made over 4% gains reacting to increased oil prices. This week could be interesting for markets as they look ahead to inflation data from Europe and the US.
Today’s snacks
DFDS, earlier today, published their monthly freight volumes and passenger numbers, revealing a limited gain of +0.6% yoy. When adjusted for new routes freight volumes, the realised change was a slight decline of -1.3%. Measured on the last 12 months, freight volumes are up 11,4%, illustrating the market has gained some momentum since the pandemic began. However, passenger numbers in August show travel restrictions are still heavily impacting the industry – passenger numbers are down 39% yoy in August and 72.5% yoy for the past 12-months. The market reaction to this news is slight; the share price fell 1.2% as the circumstances are well understood. It is likely passenger numbers will increase from here as travel restrictions continue to ease across Europe.
Elicera Therapeutics AB announced today it has been selected to present at the # ESGCT European Society of Gene & Cell Therapy (19-22 Oct) and the #PEGS Protein & Antibody Engineering Summit (2-4 Nov). Dr. Di Yu will present the iTANK platform in its first public presentation at #ESGCT. Then, Elicera’s head of research, Professor Magnus Essand, will present corresponding data and additional preclinical data on the company’s CAR T-cell therapy lymphoma treatment at #PEGS. The iTANK platform has been developed to improve the function of CAR T- cells in the fight against cancer, and the technology will be used to «strengthen our own drug candidates», said CEO Jamal El -Mosleh. Read more here: https://lnkd.in/dGs_KUnD.
Disclaimer: HC Andersen Capital receives payment from the companies for a #DigitalIR agreement.
Author: Philip Coombes
